Dr. Schneck’s Google Scholar page
Citations: 8646
h-index: 46
Last updated: April 2021


  1. Rhodes KR, Isser A, Hickey JW, Ben-Akiva E, Meyer RA, Kosmides AK, Livingston NK, Tzeng SY, Schneck JP, Green JJ. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma. ACS Appl Mater Interfaces. 2021 Feb 24;13(7):7913-7923. doi: 10.1021/acsami.0c19955. Epub 2021 Feb 12. PMID: 33573372.
  2. Isser A, Livingston NK, Schneck JP. Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy. Biomaterials. 2021 Jan;268:120584. doi: 10.1016/j.biomaterials.2020.120584. Epub 2020 Dec 5. PMID: 33338931; PMCID: PMC7856270.
  3. Hickey JW, Isser A, Salathe SF, Gee KM, Hsiao MH, Shaikh W, Uzoukwu NC, Bieler JG, Mao HQ, Schneck JP. Adaptive Nanoparticle Platforms for High Throughput Expansion and Detection of Antigen-Specific T cells. Nano Lett. 2020 Sep 9;20(9):6289-6298. doi: 10.1021/acs.nanolett.0c01511. Epub 2020 Jun 28. PMID: 32594746.
  4. Bessell CA, Isser A, Havel JJ, Lee S, Bell DR, Hickey JW, Chaisawangwong W, Glick Bieler J, Srivastava R, Kuo F, Purohit T, Zhou R, Chan TA, Schneck JP. Commensal bacteria stimulate antitumor responses via T cell cross-reactivity. JCI Insight. 2020 Apr 23;5(8):e135597. doi: 10.1172/jci.insight.135597. PMID: 32324171; PMCID: PMC7205429.
  5. Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clin Cancer Res. 2020 Jul 1;26(13):3384-3396. doi: 10.1158/1078-0432.CCR-19-3487. Epub 2020 Apr 2. PMID: 32241816; PMCID: PMC7334099.
  6. Sabatino JJ Jr, Wilson MR, Calabresi PA, Hauser SL, Schneck JP, Zamvil SS. Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis. Proc Natl Acad Sci U S A. 2019 Dec 17;116(51):25800-25807. doi: 10.1073/pnas.1915309116. Epub 2019 Nov 20. PMID: 31748274; PMCID: PMC6926057.
  7. Hickey JW, Dong Y, Chung JW, Salathe SF, Pruitt HC, Li X, Chang C, Fraser AK, Bessell CA, Ewald AJ, Gerecht S, Mao HQ, Schneck JP. Engineering an Artificial T-Cell Stimulating Matrix for Immunotherapy. Adv Mater. 2019 Jun;31(23)
  8. Isser A, Schneck JP. High-affinity T cell receptors for adoptive cell transfer. J Clin Invest. 2019 Jan 2;129(1):69-71
  9. Hickey JW, Schneck JP. Enrich and Expand Rare Antigen-specific T Cells with Magnetic Nanoparticles. J Vis Exp. 2018 Nov 17;(141).
  10. Hickey JW, Isser AY, Vicente FP, Warner SB, Mao HQ, Schneck JP. Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties. Biomaterials. 2018 Dec;187:105-116.
  11. Pruitt HC, Lewis D, Ciccaglione M, Connor S, Smith Q, Hickey JW, Schneck JP, Gerecht S. Collagen fiber structure guides 3D motility of cytotoxic T lymphocytes. Matrix Biol. 2019 Feb 16.
  12. Hickey JW, Kosmides AK, Schneck JP. Engineering Platforms for T Cell Modulation. Int Rev Cell Mol Biol. 2018;341:277-362.
  13. Schappert A, Schneck JP, Suarez L, Oelke M, Schütz C. Soluble MHC class I complexes for targeted immunotherapy. Life Sci. 2018 Sep 15;209:255-258.
  14. Kosmides AK, Necochea K, Hickey JW, Schneck JP. Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation. Nano Lett. 2018 (Epub ahead of print).
  15. Sidhom JW, Bessell CA, Havel JJ, Kosmides A, Chan TA, Schneck JP. ImmunoMap: A Bioinformatics Tool for T-cell Repertoire Analysis. Cancer Immunol Res. 2018 Feb;6(2):151-162.
  16. Rudqvist NP, Pilones KA, Lhuillier C, Wennerberg E, Sidhom JW, Emerson RO, Robins HS, Schneck J, Formenti SC, Demaria S. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. Cancer Immunol Res. 2018 Feb;6(2):139-150.
  17. Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017 Nov 2;171(4):934-949.e15.
  18. Hickey JW, Vicente FP, Howard GP, Mao HQ, Schneck JP. Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation. Nano Lett. 2017 Nov 8;17(11):7045-7054.
  19. Kosmides AK, Sidhom JW, Fraser A, Bessell CA, Schneck JP. Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. ACS Nano. 2017 Jun 27;11(6):5417-5429.
  20. Schütz C, Varela JC, Perica K, Haupt C, Oelke M, Schneck JP. Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells. Oncotarget. 2016 Oct 18;7(42):68503-68512.
  21. Tiper IV, Temkin SM, Spiegel S, Goldblum SE, Giuntoli RL 2nd, Oelke M, Schneck JP, Webb TJ. VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells. Clin Cancer Res. 2016 Aug 15;22(16):4249-58.
  22. Chiu YL, Lin CH, Sung BY, Chuang YF, Schneck JP, Kern F, Pawelec G, Wang GC. Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4 + and CD8 + T-cell responses in older adults positively correlates with response size. Sci Rep. 2016 Jan 18;6:19227.
  23. Perica K, Bieler JG, Schütz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP. Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano. 2015 Jul 28;9(7):6861-71.
  24. Meyer RA, Sunshine JC, Perica K, Kosmides AK, Aje K, Schneck JP, Green JJ. Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation. Small. 2015 Apr;11(13):1519-25.
  25. Bruns H, Bessell C, Varela JC, Haupt C, Fang J, Pasemann S, Mackensen A, Oelke M, Schneck JP, Schütz C. CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells. Clin Cancer Res. 2015 May 1;21(9):2075-83.
  26. Schütz C, Zoso A, Peng S, Bennett JD, Schneck JP, Oelke M. MHC-Ig induces memory T cell formation in vivo and inhibits tumour growth. Immun Inflamm Dis. 2014 Nov;2(3):181-92.
  27. Perica K, Kosmides AK, Schneck JP. Linking form to function: Biophysical aspects of artificial antigen presenting cell design. Biochim Biophys Acta. 2015 Apr;1853(4):781-90.
  28. Schütz C, Fleck M, Schneck JP, Oelke M. Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells. J Vis Exp. 2014 Aug 11;(90):e51859.
  29. Perica K, Tu A, Richter A, Bieler JG, Edidin M, Schneck JP. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano. 2014 Feb 24.
  30. Chiu Y-L, Shan L, Huang H-L, Haupt C, Bessell C, Canaday DH, Zhang H, Ho Y-C, Powell JD, Oelke M, Margolick JB, Blankson JN, Griffin DE, Schneck JP. Sprouty-2 regulates HIV-specific T cell polyfunctionality. J Clin Invest, 2014 Jan 2;124(1):198-202.
  31. Sunshine JC, Perica K, Schneck JP, Green JJ. Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells. Biomaterials. 2014 Jan;35(1):269-77.
  32. de Melo AB, Nascimento EJ, Braga-Neto U, Dhalia R, Silva AM, Oelke M, Schneck JP, Sidney J, Sette A, Montenegro SM, Marques ET. T-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifs. PLoS Negl Trop Dis. 2013;7(1):e1938.
  33. Webb TJ, Li X, Giuntoli RL 2nd, Lopez PH, Heuser C, Schnaar RL, Tsuji M, Kurts C, Oelke M, Schneck JP. Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer. Cancer Res. 2012 Aug 1;72(15):3744-52. Doi: 10.1158/0008-5472.CAN-11-2695. Epub 2012 May 30.
  34. Boyle S, Kolin DL, Bieler JG, Schneck JP, Wiseman PW, and Edidin M. Quantum dot fluorescence characterizes the nanoscale organization of T cell receptors for antigen. Biophys J. 2011 Dec 7:101(11):L57-9.
  35. Lee JB, Oelke M, Ramachandra L, Canaday, and Schneck JP. Decline of influenza-specific CD8+ T cell repertoire in healthy geriatric donors. Immun Ageing. 2011 Aug 16, 8:6.
  36. Xiao Z, Mohamood AS, Uddin S, Gutfreund R, Nakata C, Marshall A, Kimura H, Caturegli P, Womer KL, Huang Y, Jie C, Chakravarti S, Schneck JP, Yagita H, and Hamad AR. Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development. Am J Pathol. 2011 Aug;179(2):725-32.
  37. Chiu YL, Schneck JP, and Oelke M. HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL. J Vis Exp. 2011 Apr 11;(50). Pii:2801:do1: 10.3791/2801.
  38. Li Y, Tao SC, Zhu H, and Schneck JP. High-throughput lectin microarray-based analysis of live cell surface glycosylation. Curr Protoc Protein Sci. 2011 Feb;Chapter 12:Unit 12/9.
  39. Yue C, Oelke M, Paulaitis ME, and Schneck JP. Novel cellular microarray assay for profiling T-cell peptide antigen specificities. J Proteome Res. 2010 Nov5:9(11):5629-37.
  40. Schuetz C, Oelke M, Schneck JP, Mackensen A, and Fleck, M. Killer artificial antigen-presenting cells: The synthetic embodiment of a “guided missile.” Immunotherapy 2010 Jul;2(4):539-50.
  41. Ndhlovu ZM, Oelke M, Schneck JP, and Griffin DE. Dynamic regulation of functionally distinct virus-specific T cells. PNAS USA 2010 Feb 23;107(8):3669-74. Epub 2010 Feb 4.
  42. Oelke M and Schneck JP. Overview of HLA-Ig based “Lego-like system” for T cell monitoring, modulation and expansion. Immunol Res. 2010 Jul:47(1-3):248-56.